Finnish biomedical start-up Nightingale Health obtains CE mark for blood analysis platform
4 July 2017
Finnish biomedical startup Nightingale Health has announced today CE Marking for its blood biomarker analysis platform. The CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region